Aetas’ mission is to ‘deliver drugs that delight patients into clinical practice as quickly as possible’. This is our mission and Aetas’ ambition.

News Release

  • 2023/11

    Phase II clinical trials of M201-A injection for patients with heart failure and renal dysfunction were initiated in the first semester.

  • 2022/03

    A co-development agreement for M201-A injection for heart failure was signed in Japan.

  • 2021/01

    A Phase I repeated-dose study of M201-A injection was completed. We confirmed the effects of M201-A on Na diuresis and improvement of renal function in humans with mild renal dysfunction.

View more